GSK board conflict of interest
Executive Summary
Case Western Reserve University School of Medicine Dean Ralph Horwitz will not join GlaxoSmithKline's board as a non-executive director due to a potential conflict of interest concerning a decongestant component of a withdrawn SmithKline Beecham product. Horwitz was an investigator in a study linking phenylpropanolamine to hemorrhagic stroke. Over-the-counter medicines containing PPA were withdrawn from the market in 2000, prompting lawsuits against GSK and other drug makers (1"The Pink Sheet" Nov. 13, 2005, p. 25)...